Exagen Inc.

NASDAQ:XGN

Medical - Diagnostics & Research

Healthcare
$3.90 +3.84%

+$0.16 today

Market cap
$99.50M
Beta
2.02
P/E (TTM)
-5.2
EPS (TTM)
-$0.85
52W Low $2.59High $12.23

Volume 0.47M

Average 0.39M

XGN EBITDA Margin

EBITDA as a percentage of revenue.

Exagen Inc.NASDAQ: XGN

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin widens to -11.9%

EBITDA Margin was -11.9% in Q1 FY2026, up 5.9 pp from a year earlier. On a trailing-twelve-month basis it was -18.9%, up 1.5 pp year over year. Over 3 fiscal years it widened by 75.6 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 6 analysts of -14.1% for the fiscal year ending Dec 2026, up from -20.2% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-11.9%+4.5 pp QoQ
Last fiscal yearDec 2025
-20.2%-0.2 pp YoY
LTMMar 2026
-18.9%+1.5 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+5.9 pp-0.1 pp-6.0 pp
1 year-0.2 pp+6.1 pp+6.3 pp
3 years+75.6 pp+16.5 pp-59.1 pp
5 years+23.4 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-20.2%
Year-over-year change
-0.2pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How XGN compares with its peers on the latest reported figures

  • XGN's LTM Mar 2026 EBITDA Margin of -18.9% is the 5th highest of the 11 companies compared; the peer median is -31.8%.
  • Its year-over-year change of +1.5 pp is the 8th highest of 10, against a peer median of +11.5 pp.
  • Over three fiscal years its change of +75.6 pp compares with a peer median of +10.8 pp.
XGN Competitors Peer median
EBITDA Margin for XGN and competitors
Company Period LTM level YoY 3-year change
SMTISanara MedTech Inc.LTM Mar 20267.7% +6.7 pp+34.0 pp
NEONeoGenomics, Inc.LTM Jun 20261.7% +5.8 pp+10.8 pp
LFCRLifecore Biomedical, Inc.LTM Mar 2026-0.8% —-18.4 pp
MDXHMDxHealth S.A.FY2025-13.0% +11.5 pp+85.2 pp
XGNExagen Inc.LTM Mar 2026-18.9% +1.5 pp+75.6 pp
TKNOAlpha Teknova, Inc.LTM Mar 2026-23.8% +18.3 pp+37.0 pp
SGHTSight Sciences, Inc.LTM Mar 2026-39.8% +16.3 pp+70.4 pp
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026-62.6% -41.0 pp-64.2 pp
STXSStereotaxis, Inc.LTM Mar 2026-64.4% +23.4 pp+1.4 pp
ACRSAclaris Therapeutics, Inc.LTM Mar 2026-843.9% -542.0 pp-540.2 pp
BIOABioAge Labs, Inc.LTM Mar 2026-864.8% +3922.9 pp—
Peer median (excluding XGN) -31.8%+11.5 pp+10.8 pp

Competitors are the stored peer set for XGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue48.3M45.56M52.55M55.64M66.58M
Cost of Revenue20.59M24.21M23.09M22.53M27.78M
Gross Profit27.71M21.35M29.46M33.11M38.8M
Gross Margin57.4%46.9%56.1%59.5%58.3%
Research & Development7.24M9.88M4.87M5.38M6.25M
Selling, General & Admin44.54M52.02M47.43M41.37M46.62M
Operating Expenses51.78M67.4M52.29M46.75M52.87M
Depreciation & Amortization948K1.56M2.17M1.72M2.12M
EBITDA(23.1M)(43.66M)(19.15M)(11.15M)(13.46M)
EBITDA Margin-47.8%-95.8%-36.4%-20.0%-20.2%
Operating Income(24.07M)(46.05M)(22.84M)(13.64M)(14.07M)
Operating Margin-49.8%-101.1%-43.5%-24.5%-21.1%
Interest Income16K830K1.52M767K289K
Interest Expense2.63M2.45M2.34M2.23M4.32M
Other Income / Expenses(2.61M)(1.62M)(819K)(1.47M)(5.83M)
Income Before Tax(26.68M)(47.67M)(23.66M)(15.1M)(19.9M)
Pre-Tax Margin-55.2%-104.6%-45.0%-27.1%-29.9%
Income Tax Expense175K(282K)33K12K51K
Net Income(26.85M)(47.39M)(23.69M)(15.12M)(19.95M)
Net Margin-55.6%-104.0%-45.1%-27.2%-30.0%
EPS (Basic)(1.68)(2.77)(1.34)(0.83)(0.93)
EPS (Diluted)(1.68)(2.77)(1.34)(0.83)(0.93)
Weighted Avg Shares15.97M17.08M17.68M18.2M21.56M
Weighted Avg Shares (Diluted)15.97M17.08M17.68M18.2M21.56M

Exagen Inc.

NASDAQ:XGN

Intrinsic Alpha fair value

Locked

Current Price

$3.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.